newsfilter
← Latest News
GlobeNewswire·

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

IKT
  • Inhibikase Therapeutics reported financial results for the quarter ended June 30, 2026, alongside progress on its Phase 3 IMPROVE-PAH study for Pulmonary Arterial Hypertension.
  • The company secured regulatory approvals for the global Phase 3 trial in 26 countries, with 43 clinical sites initiated across various nations.
  • Pre-clinical \& Phase 1 data presented at the American Thoracic Society International Conference showed improved GI safety profiles \& reduced c-Kit inhibition compared to imatinib mesylate.
  • The U.S. FDA granted Orphan Drug Designation for IKT-001 in July 2026, offering tax credits, fee exemptions, \& seven years of market exclusivity.
  • In July 2026, Inhibikase sold 25 million shares to RA Capital Management for $50 million gross proceeds via an ATM facility.
  • Cash, cash equivalents, \& marketable securities totaled $159.0 million as of June 30, 2026, with capital expected to support operations through Part B topline data readout.
  • Net loss for the quarter ended June 30, 2026, was $19.6 million ($0.11 per share), compared to $9.9 million in the prior year quarter.
  • Research \& development expenses rose to $13.4 million for the quarter \& $24.2 million for the six months ended June 30, 2026.
  • Selling, general \& administrative expenses were $7.7 million for the quarter \& $15.0 million for the six months ended June 30, 2026.
  • The IMPROVE-PAH study is a two-part adaptive trial with Part A evaluating Pulmonary Vascular Resistance in ~140 patients \& Part B evaluating 6-minute walk distance in ~346 patients.
  • As of June 30, 2026, there were 132.0 million common shares outstanding along with 42.5 million pre-funded warrants.